Related references
Note: Only part of the references are listed.Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat: involvement of α-synuclein aggregation and programmed cell death
Yi-Ting Wang et al.
SCIENTIFIC REPORTS (2017)
Aggravation of brain infarction through an increase in acrolein production and a decrease in glutathione with aging
Takeshi Uemura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update
Melissa A. Bradley-Whitman et al.
ARCHIVES OF TOXICOLOGY (2015)
Evaluation of dementia by acrolein, amyloid-β and creatinine
Kazuei Igarashi et al.
CLINICA CHIMICA ACTA (2015)
Distinguishing mild cognitive impairment from Alzheimer's disease with acrolein metabolites and creatinine in urine
Madoka Yoshida et al.
CLINICA CHIMICA ACTA (2015)
Molecular Mechanisms of Acrolein Toxicity: Relevance to Human Disease
Akshata Moghe et al.
TOXICOLOGICAL SCIENCES (2015)
Distinction between mild cognitive impairment and Alzheimer's disease by CSF amyloid β40 and β42, and protein-conjugated acrolein
Mutsumi Mizoi et al.
CLINICA CHIMICA ACTA (2014)
Determination of Urine 3-HPMA, a Stable Acrolein Metabolite in a Rat Model of Spinal Cord Injury
Lingxing Zheng et al.
JOURNAL OF NEUROTRAUMA (2013)
Peripheral markers in neurodegenerative patients and their first-degree relatives
Diana Olga Cristalli et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2012)
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann et al.
ALZHEIMERS & DEMENTIA (2011)
Association of Plasma β-Amyloid Level and Cognitive Reserve With Subsequent Cognitive Decline
Kristine Yaffe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Protein-conjugated acrolein as a biochemical marker of brain infarction
Kazuei Igarashi et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2011)
Acrolein - a pulmonary hazard
Kiflai Bein et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2011)
Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease
M. A. Bradley et al.
FREE RADICAL BIOLOGY AND MEDICINE (2010)
Plasma Amyloid-beta Forms in Alzheimer's Disease and Non-Alzheimer's Disease Patients
Nathalie Le Bastard et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Role of By-Products of Lipid Oxidation in Alzheimer's Disease Brain: A Focus on Acrolein
Manjeet Singh et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Plasma Amyloid-beta as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
James K. Lui et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Determination of six hydroxyalkyl mercapturic acids in human urine using hydrophilic interaction liquid chromatography with tandem mass spectrometry (HILIC-ESI-MS/MS)
Elisabeth Eckert et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2010)
The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population
Brandie D. Wagner et al.
JOURNAL OF CYSTIC FIBROSIS (2010)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Kaj Blennow et al.
NATURE REVIEWS NEUROLOGY (2010)
Potential Role of Acrolein in Neurodegeneration and in Alzheimers Disease
Dang Thanh Nam et al.
Current Molecular Pharmacology (2010)
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Alex E. Roher et al.
ALZHEIMERS & DEMENTIA (2009)
Protein Modification by Acrolein: Formation and Stability of Cysteine Adducts
Jian Cai et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Molecular Mechanisms of 4-Hydroxy-2-nonenal and Acrolein Toxicity: Nucleophilic Targets and Adduct Formation
Richard M. LoPachin et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2009)
Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C
Alessandra Calabria Baxmann et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment
Paloma Bermejo et al.
FREE RADICAL RESEARCH (2008)
Acrolein: Sources, metabolism, and biomolecular interactions relevant to human health and disease
Jan F. Stevens et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2008)
In parkinsonian substantia nigra, α-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity
M. Shamoto-Nagai et al.
JOURNAL OF NEURAL TRANSMISSION (2007)
Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-κB1 DNA binding domain
Cherie Lambert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease
Neill R. Graff-Radford et al.
ARCHIVES OF NEUROLOGY (2007)
Aging of the brain, entropy, and Alzheimer disease
David A. Drachman
NEUROLOGY (2006)
Upregulation of endothelial heme oxygenase-1 expression through the activation of the JNK pathway by sublethal concentrations of acrolein
C. C. Wu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2006)
Acrolein in cigarette smoke inhibits T-cell responses
C Lambert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2005)
Urinary creatinine concentrations in the US population: Implications for urinary biologic monitoring measurements
DB Barr et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2005)
Age but not diagnosis is the main predictor of plasma amyloid β-protein levels
H Fukumoto et al.
ARCHIVES OF NEUROLOGY (2003)
Acrolein causes transcriptional induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549) cells
R Tirumalai et al.
TOXICOLOGY LETTERS (2002)
Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease
PD Mehta et al.
ARCHIVES OF NEUROLOGY (2000)
Share Paper
